Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder [EXTENSION OF 700054730]

Next Previous
Trial Profile

A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder [EXTENSION OF 700054730]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Lundbeck A/S

Most Recent Events

  • 01 Apr 2023 Results of pooled analysis from NCT00761306 and NCT01323478 assessing safety and efficacy of vortioxetine in the management of major depressive disorder published in the Current Medical Research and Opinion
  • 01 Sep 2015 Pooled analysis results (NCT00761306, NCT00694304, NCT00707980, NCT01323478 and NCT01152996) presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.
  • 01 Sep 2015 Pooled subgroup analysis results ((NCT00761306, NCT00694304, NCT00707980, NCT01323478 and NCT01152996)) presented at the 28th Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top